Rpo LLC Takes $39,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Rpo LLC acquired a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIRFree Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 12,947 shares of the company’s stock, valued at approximately $39,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AVIR. BML Capital Management LLC lifted its holdings in Atea Pharmaceuticals by 13.8% during the 4th quarter. BML Capital Management LLC now owns 5,462,079 shares of the company’s stock worth $16,659,000 after buying an additional 662,079 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of Atea Pharmaceuticals by 128.7% in the third quarter. Stonepine Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $5,160,000 after purchasing an additional 967,912 shares during the last quarter. Sectoral Asset Management Inc. boosted its stake in shares of Atea Pharmaceuticals by 19.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company’s stock worth $1,801,000 after buying an additional 98,924 shares during the last quarter. Newtyn Management LLC boosted its position in Atea Pharmaceuticals by 348.4% during the third quarter. Newtyn Management LLC now owns 400,000 shares of the company’s stock valued at $1,200,000 after purchasing an additional 310,803 shares during the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Atea Pharmaceuticals by 41.9% in the third quarter. GSA Capital Partners LLP now owns 278,286 shares of the company’s stock valued at $835,000 after buying an additional 82,208 shares in the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ AVIR traded up $0.09 during midday trading on Wednesday, reaching $3.70. The company’s stock had a trading volume of 69,680 shares, compared to its average volume of 385,331. The business’s 50 day moving average price is $3.81 and its two-hundred day moving average price is $3.64. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $4.69. The company has a market cap of $311.61 million, a P/E ratio of -1.84 and a beta of 0.19.

Atea Pharmaceuticals (NASDAQ:AVIRGet Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Sell-side analysts forecast that Atea Pharmaceuticals, Inc. will post -2.96 earnings per share for the current fiscal year.

About Atea Pharmaceuticals

(Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

See Also

Institutional Ownership by Quarter for Atea Pharmaceuticals (NASDAQ:AVIR)

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.